Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

GT Biopharma (GTBP) Total Non-Current Liabilities (2016 - 2017)

GT Biopharma (GTBP) has disclosed Total Non-Current Liabilities for 4 consecutive years, with $18.3 million as the latest value for Q1 2017.

  • On a quarterly basis, Total Non-Current Liabilities rose 3217.9% to $18.3 million in Q1 2017 year-over-year; TTM through Mar 2017 was $18.3 million, a 3217.9% increase, with the full-year FY2015 number at $714000.0, up 12.62% from a year prior.
  • Total Non-Current Liabilities was $18.3 million for Q1 2017 at GT Biopharma, up from $400000.0 in the prior quarter.
  • In the past five years, Total Non-Current Liabilities ranged from a high of $18.3 million in Q1 2017 to a low of $128000.0 in Q1 2014.
  • A 4-year average of $3.0 million and a median of $553000.0 in 2016 define the central range for Total Non-Current Liabilities.
  • Peak YoY movement for Total Non-Current Liabilities: increased 12.62% in 2015, then surged 3217.9% in 2017.
  • GT Biopharma's Total Non-Current Liabilities stood at $634000.0 in 2014, then grew by 12.62% to $714000.0 in 2015, then plummeted by 43.98% to $400000.0 in 2016, then skyrocketed by 4487.0% to $18.3 million in 2017.
  • Per Business Quant, the three most recent readings for GTBP's Total Non-Current Liabilities are $18.3 million (Q1 2017), $400000.0 (Q3 2016), and $528000.0 (Q2 2016).